OC
JAZZ icon

Oppenheimer & Co’s Jazz Pharmaceuticals JAZZ Stock Holding History

Oppenheimer & Co’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,398
Closed -$205K – 1451
2023
Q1 		$205K Hold
1,398
– – ﹤0.01% 1259
2022
Q4 		$223K Sell
1,398
-218
-13% -$31.9K 0.01% 1198
2022
Q3 		$215K Sell
1,616
-338
-17% -$51.4K 0.01% 1201
2022
Q2 		$305K Hold
1,954
– – 0.01% 1102
2022
Q1 		$304K Hold
1,954
– – 0.01% 1196
2021
Q4 		$249K Sell
1,954
-17
-0.9% -$2.23K ﹤0.01% 1305
2021
Q3 		$257K Sell
1,971
-59
-3% -$8.91K ﹤0.01% 1282
2021
Q2 		$361K Buy
2,030
+94
+5% +$16.3K 0.01% 1165
2021
Q1 		$318K Sell
1,936
-65
-3% -$10.7K 0.01% 1147
2020
Q4 		$330K Hold
2,001
– – 0.01% 1056
2020
Q3 		$285K Sell
2,001
-188
-9% -$23.3K 0.01% 1002
2020
Q2 		$242K Sell
2,189
-478
-18% -$52.9K 0.01% 1045
2020
Q1 		$266K Buy
+2,667
New +$345K 0.01% 940
2017
Q1 		– Sell
-3,497
Closed -$381K – 1319
2016
Q4 		$381K Buy
+3,497
New +$390K 0.01% 902
2015
Q4 		– Sell
-1,762
Closed -$234K – 1322
2015
Q3 		$234K Sell
1,762
-2,781
-61% -$479K 0.01% 1096
2015
Q2 		$800K Sell
4,543
-6,416
-59% -$1.15M 0.02% 700
2015
Q1 		$1.89M Buy
10,959
+6,773
+162% +$1.16M 0.05% 416
2014
Q4 		$685K Buy
4,186
+1,537
+58% +$255K 0.02% 719
2014
Q3 		$425K Sell
2,649
-2,449
-48% -$377K 0.01% 917
2014
Q2 		$750K Buy
5,098
+2,515
+97% +$349K 0.02% 716
2014
Q1 		$358K Sell
2,583
-614
-19% -$92.4K 0.01% 971
2013
Q4 		$405K Sell
3,197
-348
-10% -$36K 0.01% 899
2013
Q3 		$326K Sell
3,545
-135
-4% -$10.9K 0.01% 942
2013
Q2 		$253K Buy
+3,680
New +$225K 0.01% 1000

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
SC
Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Oppenheimer & Co's JAZZ Position: Q2 2023 in Review

Oppenheimer & Co sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2023, closing a stake of 1,398 shares — an estimated $205K sold.

Oppenheimer & Co first reported a position in JAZZ in Q2 2013 and held it in 24 quarters. The position peaked at $1.89M in Q1 2015. 471 funds tracked by Wall St. Rank hold JAZZ as of Q2 2023.

  • Oppenheimer & Co reported no remaining Jazz Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Oppenheimer & Co sold 1,398 Jazz Pharmaceuticals shares in Q2 2023, an estimated $205K.
  • Oppenheimer & Co first reported a position in Jazz Pharmaceuticals in Q2 2013 and held it in 24 quarters.
  • Oppenheimer & Co's Jazz Pharmaceuticals position peaked at $1.89M in Q1 2015.
  • 471 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2023.

Based on Oppenheimer & Co's 13F filing for Q2 2023, filed 3 Aug 2023.